Welcome to our dedicated page for Alkermes Plc news (Ticker: ALKS), a resource for investors and traders seeking the latest updates and insights on Alkermes Plc stock.
Alkermes plc (Nasdaq: ALKS) is a global biopharmaceutical company focused on neuroscience, and its news flow reflects both commercial execution and clinical development in this area. Company announcements emphasize proprietary products for alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, alongside a growing pipeline targeting neurological disorders such as narcolepsy and idiopathic hypersomnia.
Recent news has highlighted alixorexton, Alkermes investigational oral, selective orexin 2 receptor agonist. The company has reported positive phase 2 data from the Vibrance-1 study in narcolepsy type 1 and the Vibrance-2 study in narcolepsy type 2, and has announced that alixorexton is being evaluated in the Vibrance-3 study in idiopathic hypersomnia. In a separate update, Alkermes disclosed that the U.S. Food and Drug Administration granted Breakthrough Therapy designation to alixorexton for narcolepsy type 1, based on phase 1 and phase 2 data.
Investors following ALKS news will also see regular earnings releases, where the company reports quarterly revenues, net income, EBITDA and adjusted EBITDA, and provides updates to its financial expectations. These releases describe trends in proprietary product sales, including VIVITROL, ARISTADA and LYBALVI, and manufacturing and royalty revenues related to VUMERITY and certain long-acting antipsychotic products.
Another key theme in Alkermes news is corporate transactions and financing. The company has announced a transaction agreement, and later an amendment, to acquire Avadel Pharmaceuticals plc, adding LUMRYZ, an FDA-approved once-at-bedtime oxybate for narcolepsy, to its commercial portfolio if the transaction is completed. Related filings describe an amended and restated bridge term loan credit agreement designed to support financing of the proposed acquisition.
Visitors to the ALKS news page can expect updates on clinical trial milestones, regulatory designations, quarterly financial performance, investor conference participation and material corporate agreements. This mix of scientific, financial and strategic information provides context for understanding Alkermes evolving position in neuroscience and sleep medicine.
Alkermes plc (Nasdaq: ALKS) will participate in a fireside chat at the 5th Annual Evercore ISI HealthCONx Conference on November 29, 2022, at 2:40 p.m. ET. The event will be accessible through a live webcast on Alkermes’ investor page, with an archived version available for 14 days post-event. Alkermes is a global biopharmaceutical company focused on innovative medicines for neuroscience and oncology, with a diverse portfolio aimed at treating alcohol dependence, opioid dependence, schizophrenia, and bipolar disorder.
Alkermes plc (Nasdaq: ALKS) announced participation in a fireside chat at the Stifel 2022 Healthcare Conference on November 15, 2022, at 8:00 a.m. ET. The live webcast will be accessible on the company's website and archived for 14 days.
Alkermes is a global biopharmaceutical company focused on developing innovative treatments in neuroscience and oncology, with products aimed at alcohol and opioid dependence, schizophrenia, and bipolar disorder.
Alkermes plc (ALKS) reported Q3 2022 revenues of $252.4 million, a decline from $294.1 million year-over-year. Net sales of proprietary products rose to $199.4 million, driven by LYBALVI's launch, achieving $27.1 million. However, GAAP loss per share was $0.39, up from $0.18 a year earlier. The company plans to separate its neuroscience and oncology businesses. Financial guidance for 2022 has been raised, citing LYBALVI's performance and updates on long-acting INVEGA royalties.
Alkermes plc (Nasdaq: ALKS) plans to separate its commercial-stage neuroscience business from its development-stage oncology business to enhance focus, allocate capital effectively, and create distinct investment profiles. This strategic decision is expected to unlock shareholder value by allowing each business to pursue tailored growth strategies. The separation, anticipated in the second half of 2023, will enable Alkermes to concentrate on its neuroscience products while the new Oncology Co. will develop cancer therapies, including the investigational drug nemvaleukin. Financial details will follow.
Acorda Therapeutics reported its Q3 2022 financial results, showing a net revenue increase for both INBRIJA and AMPYRA. INBRIJA U.S. sales reached $7.8 million, up 1% year-over-year, while AMPYRA revenue rose 5% to $21.1 million. The company secured a $16.5 million arbitration award from Alkermes, relieving it from royalty payments on AMPYRA. A special stockholders meeting is scheduled for November 4, 2022, to authorize a reverse stock split to avoid Nasdaq delisting. The 2022 guidance remains unchanged, with projected AMPYRA revenue between $68-78 million.
Alkermes plc (Nasdaq: ALKS) announced the recipients of the 2022 Alkermes Inspiration Grants, awarding funding to nine nonprofit organizations addressing addiction, serious mental illness, and cancer. The grants focus on historically under-resourced communities and received nearly 250 applications. Since 2016, the program has awarded over $4.5 million to support innovative health initiatives. CEO Richard Pops highlighted the potential impact of these programs for communities across the U.S.
Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast on November 2, 2022, at 8:00 a.m. ET to discuss its third quarter financial results. The event will include updates from management regarding the company's performance. Interested parties can access the webcast through the Alkermes website and can dial in using the provided phone numbers. A replay will be available shortly after the event. Alkermes develops innovative medicines for neuroscience and oncology, with a focus on conditions such as alcohol and opioid dependence.
Acorda Therapeutics secured a favorable ruling from a three-judge arbitration panel against Alkermes PLC, with a monetary award of $15 million plus $1.5 million in pre-judgment interest. The decision relieves Acorda from paying royalties on AMPYRA sales, allowing them to source AMPYRA at competitive rates. This will enhance their profit margins and support ongoing services for patients with multiple sclerosis.
Alkermes plc (Nasdaq: ALKS) has opened applications for its 5th Annual Alkermes Pathways Research Awards, offering grants of up to $100,000 for early-career researchers focused on schizophrenia and bipolar disorder. The application period runs until Nov. 30, 2022. This initiative aims to support research addressing critical public health issues. Award recipients will be selected by an independent committee and have previously contributed to significant advancements in neuroscience. For eligibility details, visit www.PathwaysResearchAwards.com.
Alkermes plc (Nasdaq: ALKS) presented significant research findings at the Psych Congress from Sept. 17 to Sept. 20, aimed at advancing knowledge in serious mental illnesses, particularly schizophrenia and bipolar I disorder. Highlights included studies on Olanzapine/Samidorphan and long-acting injectables. Chief Medical Officer Craig Hopkinson emphasized the company's dedication to mental health research, looking forward to ongoing collaborations. Alkermes maintains a strong focus on developing innovative treatments for mental health disorders.